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Abstract
Autoimmune hyperthyroidism, Graves’ disease, can be induced by immunizing susceptible strains of mice with adenovirus
encoding the human thyrotropin receptor (TSHR) or its A-subunit. Studies in two small families of recombinant inbred
strains showed that susceptibility to developing TSHR antibodies (measured by TSH binding inhibition, TBI) was linked to
the MHC region whereas genes on different chromosomes contributed to hyperthyroidism. We have now investigated TSHR
antibody production and hyperthyroidism induced by TSHR A-subunit adenovirus immunization of a larger family of strains
(26 of the AXB and BXA strains). Analysis of the combined AXB and BXA families provided unexpected insight into several
aspects of Graves’ disease. First, extreme thyroid hyperplasia and hyperthyroidism in one remarkable strain, BXA13, reflected
an inability to generate non-functional TSHR antibodies measured by ELISA. Although neutral TSHR antibodies have been
detected in Graves’ sera, pathogenic, functional TSHR antibodies in Graves’ patients are undetectable by ELISA. Therefore,
this strain immunized with A-subunit-adenovirus that generates only functional TSHR antibodies may provide an improved
model for studies of induced Graves’ disease. Second, our combined analysis of linkage data from this and previous work
strengthens the evidence that gene variants in the immunoglobulin heavy chain V region contribute to generating thyroid
stimulating antibodies. Third, a broad region that encompasses the MHC region on mouse chomosome 17 is linked to the
development of TSHR antibodies (measured by TBI). Most importantly, unlike other strains, TBI linkage in the AXB and BXA
families to MHC class I and class II genes provides an explanation for the unresolved class I/class II difference in humans.
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Introduction
Susceptibility to Graves’ disease has long been associated with
genes of the major histocompatibility complex (MHC; HLA in
humans)(reviewed in [1]). Hyperthyroidism in Graves’ patients is
caused by autoantibodies to the thyrotropin receptor (TSHR) that
mimic the stimulatory activities of the ligand (TSH) on the thyroid
gland (reviewed in [2]). Associations between particular autoim-
mune diseases and MHC amino acid sequences [3] likely reflect
the ability of the MHC class II binding pocket to accommodate
peptides that stimulate autoreactive T cells, as shown recently for
thyroglobulin [4]. A similar mechanism would be expected to play
a role in MHC class II binding for peptides of the thyrotropin
receptor (TSHR), the autoantigen in Graves’ disease. Consistent
with this possibility, MHC class II region genes were most tightly
linked to susceptibility in a genome-wide association scan in
thyroid autoimmune disease, which included an expanded cohort
of Graves’ patients [5]. However, numerous early studies reported
associations between class I (B8) in addition to class II (DR3) genes
(for example [6]). Besides MHC class I and II, a recent study
found ‘‘a novel and major association of HLA-C in Graves’ disease
that eclipses the classical HLA-DRB1 effect’’ [7].
Graves’ disease can be induced in mice by injecting cells
expressing the human TSHR or immunization with the human
TSHR DNA in plasmid or adenovirus vectors (reviewed in [8]).
Surprisingly, in several mouse models of induced Graves’ disease,
initial studies suggested that MHC genes were less important
susceptibility factors than non-MHC genes (for example [9]);
reviewed in [10]). However, later linkage studies with recombinant
inbred (RI) strains - essentially families of related strains of mice -
provided an answer to this apparent discrepancy in terms of the
MHC gene contribution to human versus murine Graves’ disease
susceptibility. In two RI families (CXB and BXH), development of
TSHR antibodies was linked to loci in the MHC region whereas
genes on different chromosomes were linked to hyperthyroidism
[11,12]. These studies in CXB and BXH strains demonstrated a
role for MHC region genes in controlling the generation of TSHR
antibodies, at least as measured by inhibition of TSH binding to its
receptor (TBI). However, more detailed mapping of genes within
the MHC region was not performed for these two small RI
families because each only contained 13 strains.
The AXB and BXA families of strains (here abbreviated
AXBXA) were derived from parental strains A and C57BL/6 (B6).
B6 mice are also one parental strain in the CXB and BXH sets
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[13]. Mice of the B6 strain are ‘‘good antibody responders’’
to immunization with adenovirus expressing the TSHR or its
A-subunit but rarely develop hyperthyroidism [14,15]. Mice of
the A strain have not previously been examined for their response
to TSHR immunization. However, A strain mice have been
investigated for antibody induction to a variety of antigens in-
cluding phosphorylcholine [16], staphylococcal nuclease IV [17]
and hen-egg lysozyme [18] and for their responses to infectious
organisms such as Plasmodium falciparum [19].
The A strain is particularly interesting in terms of its MHC
genes compared with those in B6, C3H/He and BALB/c mice.
The latter two (C3H/He and BALB/c) are the non-B6 parents of
the BXH and CXB families, respectively. The MHC class II genes
of A mice are of the k-haplotype, as in C3H/He mice, in contrast
to the d- and b-haplotypes of B6 and BALB/c mice. Moreover, the
MHC class I genes of A strain mice are a mixture of k- and d-
haplotypes [20]. For these reasons, and because the collected
AXBXA set is significantly larger (26 strains) than the previously
studied families, we investigated the outcome of immunizing
AXBXA strains with adenovirus expressing the TSHR A-subunit.
Our findings provide several unexpected and intriguing results,
particularly in relation to the contribution of MHC region genes to
the generation of TSHR antibodies.
Results
TSHR antibodies and hyperthyroidism induced in A and
B6 mice and their F1 offspring
Mice of the A/J strain (referred to as ‘‘A’’) immunized three
times with TSHR A-subunit-Ad developed significantly lower
TSHR antibody levels (measured by TSH binding inhibition, TBI)
than either B6 mice or the F1 hybrids (B6XAF1) between the two
parental strains (Fig. 1A; p ,0.05, ANOVA). In terms of thyroid
function, no A strain mice and only one B6 mouse had elevated
serum T4 compared with Con-Ad immunized animals of the same
strain. However, two of 20 B6XAF1 mice immunized with TSHR
A-subunit-Ad were clearly hyperthyroid (Fig. 1B).
Response of recombinant AXBXA strains to A-subunit
adenovirus immunization
After immunization with A-subunit-Ad, 15 of 26 AXBXA
strains developed low TBI levels, from almost negative to ,50%
inhibition of TSH binding (Fig. 2A; strains ranked left to right for
TBI, lowest to highest). The TBI response in the other 11 strains
was more robust (.50%). TBI values were similar after two or
three immunizations (Fig. 2A, speckled versus solid bars,
respectively). In contrast, when measured by ELISA, TSHR
antibody levels for some strains were lower after the third versus
the second immunization (Fig. 2B). Moreover, the rank order for
TSHR antibodies measured by ELISA differed from that for TBI.
Focusing on the strains with strong TBI responses, TSHR
antibodies measured by ELISA were disproportionately low,
indeed almost undetectable, in strains BXA2, BXA13 and BXA1
(labeled B2, B13 and B1) (Fig. 2B versus 2A).
Turning to thyroid function, T4 levels were virtually unchanged
in AXBXA strains after two immunizations (data not shown).
However, after the third immunization, serum T4 was markedly
increased in BXA13, BXA16 and AXB13 strains (labeled B13,
B16 and A13), as reflected in the increase above pre-immunization
levels (‘‘delta’’ T4 values; Fig. 2C). Indeed, one BXA13 mouse had
the highest absolute T4 level (22 mg/dL) that we have ever
observed over 8 years in any mouse strain. Thyroid histology
confirmed that thyroid hyperplasia in BXA13 far exceeded that
routinely observed for other hyperthyroid AXBXA strains (Fig. 2F
versus 2E; euthyroid tissue in Fig. 2D) or even hyperthyroid mice
of the susceptible BALB/c strain (for example [21]. In BXA13
strains (which had the largest increase in serum T4), there was a
striking discordance between the very strong serum TBI activities
Figure 1. TSHR antibodies measured by TSH binding inhibition
(TBI) and serum T4 in A/J, B6AF1 and B6 mice immunized three
times with TSHR A-subunit-adenovirus; B6 data from Chen
et al [15]. Values are shown for individual mice (white, A/J; grey, B6XA
F1; black, B6). A) TBI (% inhibition of labeled TSH binding to its
receptor). Broad black bars indicate the mean TBI values; horizontal
broken lines: mean + 2SD for control-adenovirus immunized mice. *,
values significantly greater than for B6 mice (ANOVA; Holme -Sidak
method, p,0.05). B) T4 (mg/dL). Speckled box: mean + 2SD for Con-Ad
immunized mice of each strain.
doi:10.1371/journal.pone.0021378.g001
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(,70%; Fig. 2A) and the virtual absence of TSHR antibodies
detectable by ELISA (Fig. 2B).
TSAb activity
Thyroid stimulating antibody (TSAb) activity was measured
in AXBXA strains after the third A-subunit-Ad immuniza-
tion. Separate assays were performed using CHO cells stably
expressing the human-TSHR or the mouse-TSHR. The rank
order for TSAb values corresponded approximately to that for
TBI. Strains with the highest TSAb values, specific for the
human- or the mouse-TSHR, generally had high TBI levels
(Fig. 3A and B versus Fig. 2A). Another measure of TSAb
activity, the ratio of human:mouse-TSHR responsivity (Fig. 2C),
indicated preferential recognition of the human versus the
mouse-TSHR consistent with the immunogen being the human-
TSHR A-subunit.
Linkage analysis in AXBXA mice
Quantitative trait loci (QTL) were mapped using the AXBXA
strain database files [13,22] for the following parameters: TSHR
antibodies measured by TSH binding inhibition (TBI), ELISA,
TSAb activity (specific for the human-TSHR, the mouse-TSHR,
or the human:mouse TSAb ratio); T4 levels and the difference
‘‘delta’’) between T4 after immunization and baseline.
Figure 2. TSHR antibodies, T4 and thyroid histology in 26 AXBXA strains immunized three times with TSHR A-sub-Ad. Data are
ranked from left to right according to TBI activity (after the third immunization) from the strain with the lowest TBI (AXB1, abbreviated A1) to the
strain with the highest TBI activity (AXB13, A13). Grey boxed areas with an asterisk link panels A,B and C for the strains with the greatest increase
(delta) in T4, namely BXA13, BXA16 and AXB13 (B13, B16 and A13, respectively). A) TBI (inhibition of labeled TSH binding to its receptor) and B) TSHR
antibody measured by ELISA (OD 490 m). Bar graphs represent the mean +SEM (5–6 mice/strain) after 2 immunizations (2x, speckled bars) or 3
immunizations (3x, solid bars). The vertical dashed line indicates the cut-off between strains with less than 50% TBI (to the left) and greater than 50%
TBI (right of the line). C) T4 increase (delta T4 3x). Data shown as bars graphs for the mean + SEM. D, E, F) Representative thyroid histology
(magnification 10x) for euthyroid mouse (D), hyperthyroid mouse with T4 10 mg/dL (E) and extremely hyperthyroid mouse with T4,20 mg/dL (F, as in
BXA13 strains).
doi:10.1371/journal.pone.0021378.g002
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The most striking linkage was between TBI and a locus on Chr 17
(twin peaks at,33 and,37 Mb) with likelihood ratio statistic (LRS)
values of 24.2 (after two immunizations) and 32.5 (after three
immunizations)(Table 1). The latter LRS value (corresponding to
LOD score 7.05) greatly exceeds the LRS cut-off of 20–25 usually
required to reach genome-wide significance of p,0.05. TSHR
antibodies measured by ELISA (after two and three immunizations)
were linked to loci on Chr 1, with a higher LRS value after the second
than after the third immunization (Table 1), likely associated with
higher ELISA antibody values after two than after three adenovirus
injections (Fig. 2B). TSAb specific for the mouse-TSHR (m-TSAb)
was linked to the same loci on Chr 17 region as TBI (Table 1).
However, TSAb specific for the human-TSHR (h-TSAb) and the
ratio of TSAb activities with the human or mouse TSHR (h:m-
TSAb) were linked to a locus on the distal end of Chr 12. In terms of
thyroid function, the absolute serum T4 level and the increase in T4
(‘‘delta T4’’) after three immunizations were linked to loci on Chr 16.
Linkage for TSHR antibodies in AXBXA, CXB and BXH sets
compared with previous reports on AXBXA responses to
other immune challlenges
We compared linkage data for induced TSHR antibodies in the
AXBXA set with our previous findings in CXB and BXH sets
[11,12,23] and with information on the responses in the AXBXA
set to other immune challenges [20,24]:-
(a) The most notable similarity is the near identical linkage
between TBI and the Chr 17 locus (present study) and
induced antibodies to human Factor IX (anti-Factor IX)
[20](Fig. 4A). In addition, the linkage on Chr 17 for TBI
overlapped in all three RI sets. However, for BXH and
CXB mice, LRS values were lower, broader and spanned
the two AXBXA peaks (Fig. 4B). Variability in the
response of AXBXA strains to infection with Histoplasma
capsulatum (measured as spleen weight) was also linked to
the Chr 17 locus but the major peak was distal to the
peaks for TBI and anti-factor IX (Fig. 4C versus Fig. A
and B).
(b) TSAb activities, specific for the human-TSHR, or the h:m-
TSAb ratio, in AXBXA, BXH and CXB sets were all linked
to loci on the distal end of Chr 12 (Fig. 4D).
(c) Linkage to Chr 1 loci for TSHR ELISA antibodies in
AXBXA mouse strains overlapped to a minor extent with
the values for BXH strains (Fig. 4E) or versus anti-factor IX
antibodies in AXBXA strains (Fig. 4F).
Contribution of parental B6 alleles versus non-B6 alleles
Information on the contribution of parental alleles is provided
by the additive effects for linkage. Positive additive effects indicate
the contribution from A-strain alleles (A strain mice) whereas
Figure 3. Thyroid-stimulating antibodies (TSAb) in AXBXA strains after 3 immunization with A-sub-Ad. Data are shown for TSAb
specific for the human-TSHR (A), the mouse-TSHR (B), and as the ratio of human: mouse TSAb (C). Error bars represent SEM (A and B). As in Fig. 2, the
grey boxed areas with an asterisk link panels A), B) and C) for the three most hyperthyroid strains, namely BXA13, BXA16 and AXB13 (B13, B16 and
A13, respectively); also, the vertical dashed line indicates the ‘‘cut-off’’ for strains with less than 50% TBI.
doi:10.1371/journal.pone.0021378.g003
Susceptibility Genes for Murine Graves’ Disease
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21378
negative additive effects indicate the contribution from B-alleles
(B6 strain mice)(see Methods).
(a) TBI:- the negative additive effects (220) indicate the
contribution from B6 variant genes (Fig. 5, top left; red
ellipse). In contrast, the strong positive additive effects
(.8000) demonstrate that anti-Factor IX levels are increased
by alleles inherited from the A-strain (Fig. 5, bottom left,
purple ellipse).
(b) TSAb, in AXBXA, BXH and CXB sets, TSAb measure-
ments involving the human-TSHR were linked to Chr 12 loci.
For AXBXA strains, the negative additive effects indicate the
contribution of B alleles (red ellipse. Fig. 5 top right); in CXB
and BXH strains, the positive additive effects reflect the
contribution of alleles from BALB/c and C3H/He strains
(blue and pink ellipses, respectively; Fig. 5, right middle and
bottom panels). Incidentally, in the AXBXA set, TSAb
specific for the mouse-TSHR was linked to the same Chr 17
locus as TBI (Table 1) and, as for TBI, B alleles increased
this trait (data not shown).
LRS values for TSAb activities in the three RI sets individually
are relatively low (Table 1; [23]. However, combined linkage
analysis increased the LOD scores for linkage between TSAb
(specific for the human-TSHR or the human:mouse-TSAb ratio)
and Chr 12 (Table 2).
Genes on Chr 17 linked to TBI activity
The location of class I, II and III MHC genes is illustrated
schematically (Fig. 6). Apart from upstream DMb1, MHC class II
genes (Ab1, Aa, Eb1, Eb2, Ea, Dma and DMb2) lie between class I
genes H2-K and the class III genes which include complement,
tumor necrosis factor, lymphotoxin, lymphocyte antigen 6 and
heat shock proteins (C,Tnf, Ltn, Ly-6 and Hsp). The distal group of
MHC genes encode class I molecules (D, M and T).
The strongest TBI linkages in the AXBXA set (LOD .7) are to
the MHC class II gene DMb1 and to a class I gene, tentatively
assigned as H2-M3 (Fig 6). In addition, TBI in AXBXA strains is
linked to the class II gene H2-Ab1 and the class I gene H2-Q6.
AXBXA LOD scores exceed those for the BXH and CXB sets
(3.83 and 3.57, respectively). In BXH strains, TBI is linked to the
class III gene Hspa1 and tentatively linked in CXB strains to
Lysg5c. Some linkages between TBI and Chr 17 lie outside the
MHC region (with no known candidate genes): upstream (BXH
set) and downstream of MHC genes (CXB, AXBXA)(Fig. 6,
Table 2).
Discussion
Recombinant inbred AXBXA strains immunized with TSHR
A-subunit adenovirus provided insight into two aspects of Graves’
disease. First, we observed more severe hyperthyroidism in one of
these strains than we previously observed in any other inbred
strain. Second, our data are the first to implicate MHC class I
genes as contributing to the variability in the TSHR antibody
response in an induced mouse model of Graves’ disease. Neither of
these outcomes was anticipated from studying the parental strains
and the F1 obtained by crossing A to B6 strains. Briefly, TSHR
antibody responses (measured as TBI) were low in A-strain mice
and high in the F1, as in B6 mice, demonstrating that high
responder B6 parental genes dominate the low responder A-strain
parental variants. Moreover, although uncommon, some F1 mice
became hyperthyroid. Consequently, it seemed likely that studying
the relatively large AXBXA set (26 members) would contribute to
understanding the genetic susceptibility to induced Graves’
disease. However, the overall impact was far greater than we
had expected.
Very severe hyperthyroidism associated with extreme thyroid
follicular cell hyperplasia (Fig. 2F) was observed in BXA13 mice.
We offer what we believe to be a likely explanation for this
phenomenon. TSHR antibody assays for inhibition of TSH
binding (TBI) and TSHR activation (TSAb) measure pathogenic
(‘functional’) antibodies. Immunization of BALB/c and B6 mice
with A-subunit adenovirus induces both functional TSHR
antibodies detectable by TBI and TSAb as well as antibodies
measured by ELISA (for example [15]). Pathogenic (or ‘function-
al’) TSHR antibodies, including the human monoclonal stimulat-
ing antibody M22 [25], have little or no recognition of the
purified, recombinant TSHR A-subunit protein coated on an
ELISA plate. Despite high TBI values, BXA13 mice were virtually
negative for TSHR-ELISA antibodies.
It should be noted that neutral TSHR antibodies have been
detected in Graves’ sera by flow cytometry [26] or by inhibiting
monoclonal antibody binding to ELISA plates coated with
peptides corresponding to the TSHR cleavage region, amino acid
residues 316–366 [27]. Such neutral antibodies may play a role in
exacerbating the autoimmune response in Graves’ disease [27]. In
contrast, ELISA-type TSHR antibodies induced in mice bind
predominantly to the extreme amino-terminus of the TSHR [28].
In fact, the A-subunit used for immunization lacks the cleavage
region recognized by most neutral TSHR antibodies [27].
Table 1. Chromosomal linkage for TSHR antibodies and
thyroid function in AXBXA RI mice immunized with TSHR A-
subunit-Adenovirus.
Trait LRS LODa Chr Locus Mb h-Chrb
TSHR
Antibodies
TBI (3x) 32.52 7.05 17 rs3672987 33.247 19
rs13482968 37.269
ELISA (2x) 20.19 4.38 1 rs4222856 180.251 1
CEL-1_
178482360
180.396
ELISA (3x) 15.08 3.27 1 D1Mit356 174.819 FcR-like6d
rs4136041 177.367
m TSAb (3x)c 14.10 3.06 17 rs3672987 33.247 19
rs13482968 37.269
h TSAb (3x) c 15.11 3.28 12 D12Nds2 115.135 14
rs3686531 120.968
Thyroid
Function
T4 (3x) 14.52 3.15 16 rs4192837 60.329 3
rs4195972 64.435
Delta T4 (3x) 10.45 2.27 16 rs4202837 73.290 3
rs4203607 73.919
Loci and their chromosomal locations (megabases, Mb) are given for traits with
the highest LRS (Likelihood Ratio Statistic) scores after two or three (2x or 3x)
immunizations; significant linkage in bold.
aLOD scores: calculated from LRS/4.61.
bInformation on the corresponding human (h) Chr or likely Chr is included.
cLinkage analysis performed using SEM;
dFc receptor-like 6 (174.528328 Mb). Note: Lower LRS values:- TBI (2x): LRS 24.21
(33.2472, 37.2686 Mb);TSAb h:m ratio (3x): LRS 14.85 (115.135, 120.968 Mb).
doi:10.1371/journal.pone.0021378.t001
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Moreover, as described below, TSHR-ELISA antibodies in mice
protect, rather than exacerbate, responses to the TSHR.
Pre-treating BALB/c mice with TSHR A-subunit protein
before A-subunit adenovirus immunization attenuated hyperthy-
roidism by ‘‘deviating’’ the humoral response from pathogenic
(TBI and TSAb positive) towards TSHR-ELISA antibodies [29].
Consistent with the extreme degree of hyperthyroidism, the
qualitative balance in the BXA13 strain was almost entirely
towards functional TSHR antibodies, with minimal ELISA-
positive antibodies. Even BALB/c mice, the most susceptible to
developing hyperthyroidism in our induced Graves’ disease model,
develop high levels of TSHR-ELISA antibodies as well as
functional TSHR antibodies (for example [21]). Therefore, the
BXA13 strain immunized with the TSHR A-subunit may
resemble human Graves’ patients more closely than do similarly
immunized BALB/c mice. Unlike some other autoimmune
diseases such as type I diabetes, Graves’ disease occurs only in
humans and there are no spontaneous animal models of the
disease. The importance of our present finding is that the use of
BXA13 mice may provide a major enhancement in studying
induced Graves’ disease.
Our initial goal for investigating mice of the AXBXA set was to
expand our studies of the genetic basis for susceptibility to induced
hyperthyroidism and TSHR antibodies. In this set, elevated serum
T4 was linked to a locus on Chr 16. This linkage was not observed
in comparable studies of BXH and CXB strains (Chr 3,
13)[11,12]. As previously observed [30], linkage of baseline T4
in AXBXA strains (Chr 2)[30] is distinct from linkage in BXH and
CXB strains (Chr 1, 11 and 13). Similarly, TSHR antibodies
measured by ELISA were linked to Chr 1 but the loci were
different from those previously observed in CXB and BXH strains
[11,12]. In contrast, TSAb activity was linked to the same distal
region on Chr 12 noted for BXH and CXB strains [23]. Indeed,
combined linkage for the three RI sets (AXBXA, CXB and BXH)
increased the LOD score from 3.54 in two RI sets [23] to 5.71 in
three RI sets over a broad interval (113.595–117.869 Mb). More
than half the genes within this interval (54%) encode immuno-
globulin heavy chain V region genes. The high frequency of VH
genes in this locus suggests that VH gene differences between
mouse strains underlie the susceptibility (or lack thereof) to develop
antibodies capable of activating the TSHR (as discussed previously
[23]).
The most striking observation for the AXBXA set was the very
strong linkage between TSHR antibodies measured by TBI and a
broadly defined MHC region on Chr 17 with LOD scores rising
from 5.25 after two immunizations to 7.05 in mice immunized
three times. The same Chr 17 locus was linked in AXBXA strains
immunized to develop antibodies to Factor IX [20] and, albeit to a
lesser extent, to spleen responses after infection with Histoplasma
capsulatum [24]. Linkage to Chr 17 is not a general characteristic of
Figure 4. Chromosomal linkage in AXBXA, CXB and BXH sets for induced antibodies TSHR antibodies [present study; [11,12] as well
as other immune response in AXBXA strains: antibodies to human factor IX induced using adenovirus [20] and spleen weight in
Histoplasma capsulatum infected mice [24]. For each panel, chromosomal location is on the X-axis (Mb) and LRS values are on the Y-axis. Left
panels: Chr 17 linkage for A) TBI 2x and anti-factor IX in AXBXA strains; B) TSHR antibodies measured by TBI after 2 immunizations in AXBXA, BXH and
CXB strains; C) TBI (2x) and H. capsulatum infection (spleen weight) in AXBXA strains. Right panels: D) Chr 12 linkage for hTSAb in AXBXA, m:h TSAb in
BXH and h:m TSAb in CXB strains; E) Chr 1 linkage for antibodies measured by ELISA in AXBXA and BXH strains; F) anti-TSHR by ELISA 2x versus anti-
factor IX in AXBXA strains.
doi:10.1371/journal.pone.0021378.g004
Susceptibility Genes for Murine Graves’ Disease
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AXBXA strains to immunization: the major linkage peak for
Histoplasma susceptibility is downstream of the MHC region.
Moreover, variability in anti-cardiac sacrolemmal antibodies that
develop in AXBXA mice after Coxsackie infection is linked to Chr
5 and 7 [31].
Linkage between Chr 17 loci and both TBI and antibodies to
human Factor IX raised the following question: because both
antibodies were induced using human-adenovirus vectors, do these
linkages merely reflect susceptibility to adenovirus? This issue was
refuted by information on additive effects: B-alleles (negative
additive effects) increase TBI whereas A-alleles (positive additive
effects) increase anti-Factor IX. Moreover, the major locus for
susceptibility to mouse-adenovirus (which resembles human
adenoviruses in structure and genome organization) maps to
Chr 15 [32], not to Chr 17. Together with the additive effect data,
this information supports the conclusion that linkage between TBI
and Chr 17, or between anti-Factor IX and the same Chr 17
locus, is unrelated to the adjuvant effects of adenovirus and is
specific for the two very different immunogens.
Finally, it was possible to putatively assign MHC genes linked to
TBI in AXBXA strains (present study) and in CXB and BXH
strains [11,12]. In the AXBXA set, TBI is strongly linked to DMb1
(class II) and H2-Q6 and H2-M3 (class I) and to a lesser extent to
H2-Ab1 (class II). Although the role of class I antigens is not
understood, strong linkage between TBI and DMb1 suggests that
peptide loading to MHC class II antigens plays a critical role in
AXBXA responses to A-subunit immunization. Potentially
interesting is TBI linkage to the class III genes heat shock protein
(BXH set) and a lymphocyte antigen-6 family member (CXB set).
The large family of lymphocyte antigen-6 proteins (27 in humans
and 37 in mice), have putative immune roles [33]. Heat shock
proteins have previously been associated with Graves’ disease (for
example [34,35]), although their specific role in thyroid autoim-
munity (as distinct from cellular processes in general) is enigmatic
[36]. It is intriguing that, at least in some mouse strains, heat shock
proteins may be involved in the development of TSHR antibodies.
In conclusion, investigations in AXBXA recombinant inbred
mice immunized with TSHR A-subunit adenovirus provided
unexpected insight into several aspects of Graves’ disease. First,
extreme thyroid hyperplasia and hyperthyroidism in one AXBXA
strain likely reflects its inability to generate ELISA-type TSHR
antibodies ot the type not observed in Graves’ patients. For this
reason, BXA13 strain immunized with A-subunit-adenovirus may
provide the most suitable mouse strain for investigating human
Graves’ disease. Second, linkage data from AXBXA mice
strengthen the case for the contribution of immunoglobulin heavy
chain variable region genes to the generation of thyroid
stimulating antibodies. Third, genes within and outside the
Figure 5. Influence of parental genes (B6 or non-B6) on linkage between TBI and Chr 17 (left panels) and between TSAb and Chr 12
(right panels) in AXBXA, CXB and BXH sets. Also included are data for antibodies to Factor IX in AXBXA mice. LRS values are plotted together
with the ‘‘Additive effect’’ which is defined as:- half the difference in the mean phenotype of all cases homozygous for one parental allele at this
marker minus the mean of all cases homozygous for the other parental allele at this marker. For AXBXA strains: positive additive effects indicate that
A alleles increase trait values; negative additive effects indicate that B6 alleles (red ellipse) increase trait values. Chromosomal location is on the X-axis
(Mb); LRS values on the left Y-axis; additive values on the right Y-axis. Elipses highlight Chr locations for peak LRS values. Left: TBI activity in AXBXA
mice (upper panel) and anti-human factor IX (lower panel, from [20]. Additive effects:- positive, A alleles (purple ellipse); negative, B6 alleles (red
ellipse). Right panels: Upper right, TSAb specific for the human TSHR in AXBXA mice; middle right, TSAb human: mouse (h:m) ratio in CXB strains
(from [23]; lower right, TSAb mouse: human (m:h) ratio in BXH mice (from [12]. Additive effects:- positive, C3H/He allelles (blue ellipse) or BALB/c (pink
ellipse); negative, B6 alleles (red ellipse).
doi:10.1371/journal.pone.0021378.g005
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MHC region are linked to the generation of TSHR antibodies
(measured by TBI). Moreover, the finding that TBI in AXBXA
strains is linked to both class I and class II MHC region genes may
provide an explanation for conflicting findings regarding the two
classes of these genes in different human populations.
Materials and Methods
Immunization of mice with TSHR A-subunit adenovirus
Female mice of the following 26 strains (5 to 8 weeks of age; The
Jackson Laboratory, Bar Harbor, Maine) were studied:- A/J and
B6AF1J (hereafter referred to as ‘‘A’’ and ‘‘B6AF1’’); AXB/PgnJ
strains 1, 2, 4, 5, 6, 8, 10, 12, 13, 15, 19a (formerly AXB18), 23,
24; BXA/PgnJ strains 1, 2, 4, 7, 8, 11, 12, 13, 14, 16, 24, 25, 26.
Adenovirus expressing the human TSHR A-subunit (amino acid
residues 1–289, A-subunit-Ad) [21] and control adenovirus lacking
an inset (Con-Ad)[37] were propagated in HEK293 cells
(American Type Culture Collection, Manassas, VA), purified on
CsCl density gradients and viral particle concentration was
determined from the absorbance at 260 nm [38].
A and B6AF1 strains were immunized intramuscularly three
times with A-subunit-Ad (108 particles per injection)(10–20 mice/
strain) or Con-Ad (5 mice/strain) on three occasions at three
weekly intervals as described [21]. Data previously obtained for B6
mice immunized in the same way [15] are included for
comparison. Baseline T4 values in AXBXA strains were published
recently [30]: briefly, before immunization, blood samples were
drawn from individual mice in each AXB or BXA strain (5–6
mice/strain); sera were pooled for each strain and analyzed in
duplicate for T4. Prior studies in CXB and BXH mice had
demonstrated consistency for individual mice in pre-immunization
samples [11,12]. Subsequently, for the current study, AXBXA
strains were immunized with A-subunit-Ad (108 particles per
injection) three times at three weekly intervals. Blood was drawn
one week after the second immunization and mice were
euthanized four weeks after the 3rd injection to harvest blood
and thyroid glands.
Figure 6. MHC region genes on mouse Chr 17 in relation to TBI linkage in AXBXA, CXB and BXH RI sets. Genes are clustered and
assigned arbitary colors and bar lengths to distinguish between the following:- Green: MHC Class I genes (K, -O,; -D1 and -Q; H2 -T, -L and -M; Purple,
MHC Class II genes: H2-Ab1, Aa, Eb1, Eb2, Ea, as well as Dm and Tap; Brown: MHC class III genes complement, tumor necrosis factor, lymphotoxin,
heat shock proteins (C, Tnf, Ltn, hsp) and 5 groups of lymphocyte antigen-6 (Ly-6): Ly6g6c,d,e and Ly6g5c,and b; Black: Non-MHC genes. LOD scores
are for RI mice immunized 3x (AXBXA) or 2x (BXH and CXB). Solid elipses: genes at or very close to loci for maximum LOD scores; dashed elipses:
closest genes (insufficient markers for precise localization).
doi:10.1371/journal.pone.0021378.g006
Table 2. Combined linkage for Chr 12 loci for TSHR
antibodies measured by TSAb in AXBXA (present study), BXH
and CXB sets [23].
Trait
Individual
LOD
Interval
(Mb) X2 p
Com
LODb
TSAba
AXBXA (3x) h 3.28
BXH (3x) h 4.05 113.270–
114.345c
48.32 1.01923E
-08
7.99
CXB (2x) m 3.16
TSAb
ratio (h:m)
AXBXA (3x) 3.23
BXH (3x) 3.14 113.595–
117.869d
36.80 1.93028E
-06
5.71
CXB (2x) 1.62
aTSAb was assayed using cells expressing human (h) or mouse (m) TSHR. Mice
received two or three immunizations (2x or 3x, respectively).
bComb LOD: combined LOD score.
c113.27–114.345 Mb: 14/40 (35%) IgH V region genes.
d115.135–117.869 Mb: 14/26 (54%) IgH V region genes.
doi:10.1371/journal.pone.0021378.t002
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Assays for TSHR antibodies
TSHR antibodies were investigated using three assays: TSH
binding inhibition (TBI), ELISA using TSHR A-subunit protein,
and a bioassay for thyroid stimulating antibody (TSAb). TBI was
determined using a commercial kit (Kronus, Boise, ID): serum
aliquots (25 ml) were incubated with detergent solubilized TSHR;
125I-TSH was added and the TSHR-antibody complexes were
precipitated with polyethylene glycol. TBI values were calculated
from the formula:- [1- (TSH binding in test serum - non-specific
binding)/(TSH binding in normal serum - non-specific binding)]
X 100.
TSHR antibodies (IgG class) were measured by ELISA as
previously described [21]. Briefly, recombinant TSHR A-subunit
protein secreted by Chinese Hamster Ovary cells with an
amplified transgenome [39] was purified from culture superna-
tants by affinity chromatography [40]. ELISA wells were coated
with A-subunit protein (1 mg/ml) and incubated with test sera
(duplicate aliquots, 1:100 dilution). Antibody binding was detected
with horseradish peroxidase-conjugated mouse anti-IgG (Sigma
Chemical Co., St. Louis, MO) and the signal was developed with
o-phenylenediamine and H2O2. Data are reported as the optical
density (OD) at 490 nm.
TSAb activity specific for the human-TSHR or the mouse-
TSHR was assayed as descrribed previously [23]. Briefly, Chinese
hamster ovary (CHO cells expressing the human-TSHR (or the
mouse-TSHR) were plated in 96 well plates and, when confluent,
incubated (60 min, 37uC) with test sera diluted 1:20 in Ham’s F12
supplemented with 10 mM Hepes, pH 7.4, and 1 mM isobutyl-
methylxanthine. After aspirating the medium, intracellular cAMP
was extracted with ethanol, evaporated to dryness and resus-
pended in Dulbecco’s PBS. Samples (20 ml) were assayed using the
LANCE cAMP kit (PerkinElmer, Boston MA). TSAb activity was
expressed as a percentage of cAMP values attained with sera from
control, unimmunized mice.
Serum thyroxine and thyroid histology
Total thyroxine (T4) was measured in undiluted mouse serum
(25 ml) using a radioimmunoassay kit (Diagnostic Products
Corporation, Los Angeles, CA). T4 values were computed from
standards in the kit and expressed as mg/dL at base-line and after
two immunizations (2x) or three immunizations (3x). In addition,
to incorporate baseline thyroid function, we calculated the change
(delta) after two or three immunizations. Thyroid glands were
fixed in buffered formaldehyde (pH 7.4), paraffin-embedded and
serial sections were stained with hematoxylin and eosin (Research
Animal Diagnostic Laboratory, University of Missouri, Columbia,
MO).
Statistical analyses
Significant differences between responses in different groups
were determined by Mann Whitney rank sum test or, when
normally distributed, by Student’s t test. Multiple comparisons
were performed using analysis of variance (ANOVA). Tests were
performed using SigmaStat (Jandel Scientific Software, San
Rafael, CA).
Genetic linkage analysis
Putative quantitative trait loci (QTL) involved in traits of the
AXBXA set before and after A-subunit-Ad immunization were
mapped using the genotype files for AXB/BXA RI strains generated
byWilliams et al. [13] embedded in GeneNetwork. This genotype file
consists of 2446 markers with unique strain distribution patterns
(www.genenetwork.org/dbdoc/AXBXAGeno.html). The probabili-
ty of linkage between our traits and previously mapped genotypes was
estimated at,1 centiMorgan intervals (,2 megabase; Mb) along the
entire genome, except for the Y chromosome. To establish criteria for
suggestive and significant linkage, a permutation test was performed
(1000 permutations at 1-centimorgan intervals)[41]. This test
compares the peak likelihood ratio statistics (LRS; LRS=LOD64.6,
where LOD is the logarithm of the odds) obtained for the properly
ordered data with the distribution of peak LRS scores obtained from
1000 random permutations of the same data. Additive effects were
also estimated. In AXBXA strains, a positive additive effect indicates
that an A allele increases trait values at a particular locus or marker; a
negative additive effect indicates that a B allele increases trait values.
The primary phenotype data (10 traits) have been entered into the
mouse AXB/BXA Phenotype database on GeneNetwork (www.
genenetwork.org) under the trait accession identifiers GN 10158 to
10166, 10172 to 10175 and can be found by searching for the name
‘‘McLachlan’’.
For some parameters, we combined the LRS values for AXB/
BXA strains with our previous findings for CXB or BXH strains
[11,12] to provide linkage data for en entire collection of 52 RI
strains that all share a B6 parental strain. Following the combined
linkage analysis approach for neuron number in two or more
families [42], we calculated the probability associated with a X2
value equal to: 22 (lnPAXBXA + lnPCXB + lnP BXH)) with 6 degrees
of freedom, where lnPAXBXA, lnPCXB and lnPBXH are the natural
logarithms of the probabilities derived independently for the three
RI families in the same chromosomal interval. Combined linkage
data are provided as LOD scores (convertible to LRS values by
multiplying by 4.61, as described above). In the combined
analyses, ‘‘point-wise’’ p values are provided for the single points
examined (as opposed to genome-wide tests which examine few
hundred points).
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